Cargando…
The Importance of and Challenges with Adopting Life-Cycle Regulation and Reimbursement in Canada
Regulatory and reimbursement decisions for drugs and vaccines are increasingly based on limited safety and efficacy evidence. In this environment, life-cycle approaches to evaluation are needed. A life-cycle approach grants market approval and/or positive reimbursement decisions based on an undertak...
Autores principales: | McPhail, Melanie, McCabe, Christopher, Regier, Dean A., Bubela, Tania |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Longwoods Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935925/ https://www.ncbi.nlm.nih.gov/pubmed/35319446 http://dx.doi.org/10.12927/hcpol.2022.26726 |
Ejemplares similares
-
Should Canada adopt managed access agreements in Canada for expensive drugs?
por: McPhail, Melanie, et al.
Publicado: (2023) -
Lessons from Canada’s notice of compliance with conditions policy for the life-cycle regulation of drugs
por: McPhail, Melanie, et al.
Publicado: (2023) -
Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness
por: McPhail, Melanie, et al.
Publicado: (2022) -
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada
por: Regier, Dean A., et al.
Publicado: (2022) -
Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges
por: Knowles, Lori, et al.
Publicado: (2017)